39 results
DEFM14A
KDNY
Chinook Therapeutics Inc
10 Jul 23
Proxy related to merger
4:01pm
in the United States.
“Good Manufacturing Practices” mean standards for the manufacture, processing, packaging, testing, transportation, handling
PREM14A
KDNY
Chinook Therapeutics Inc
27 Jun 23
Preliminary proxy related to merger
4:02pm
.
“Good Manufacturing Practices” mean standards for the manufacture, processing, packaging, testing, transportation, handling and holding of drug products
DEFA14A
KDNY
Chinook Therapeutics Inc
12 Jun 23
Additional proxy soliciting materials
7:05am
are not less stringent than in the United States.
“Good Manufacturing Practices” mean standards for the manufacture, processing, packaging, testing
8-K
EX-2.1
KDNY
Chinook Therapeutics Inc
12 Jun 23
Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG
7:00am
stringent than in the United States.
“Good Manufacturing Practices” mean standards for the manufacture, processing, packaging, testing, transportation
8-K
EX-1.1
KDNY
Chinook Therapeutics Inc
25 May 22
Chinook Therapeutics Announces Pricing of a $105 Million Public Offering
4:09pm
applicable to the Company and its Subsidiaries and the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing
8-K
EX-1.1
0utp3l
10 Nov 21
Chinook Therapeutics Announces Pricing of an Upsized $160 Million Public Offering
5:24pm
S-4
EX-10.1
eeeaig i6
22 Jul 20
Registration of securities issued in business combination transactions
12:00am